Replies to post #22158 on Ariad Pharmaceuticals Inc fka ARIA

[gdollasign]

From the Ariad site:

The latest candidate to enter ARIAD’s early-stage pipeline, AP26113, is a unique small-molecule that in preclinical studies has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) AND epidermal growth factor receptor (EGFR).



So Don, why wouldnt you expect EGFR study results?